HOME >> BIOLOGY >> NEWS
Experimental Biology 2007: Today's Research, Tomorrow's Health, April 28-May 2

d novel therapies based on molecules of the innate immune system.

The American Society for Pharmacology and Experimental Therapeutics offers symposia on cannabinoids (a chemical compound in cannabis or marijuana), endocannabinoids (a marijuana-like substance) and pain associated with inflammation, stress, psychiatric disorders, neurodegenerative disorders, and other disorders; the future of pharmacogenomics and its clinical applications; nanotechnology in disease therapeutics; osteoporosis and bone research (a symposium subtitled "no time to be bad to the bone"); toxicology of nanomaterials (including effects on the skin and lungs); the ways in which nicotine modulates adolescent brain plasticity, interacts with other drugs during sensitive developmental periods, and, when used along with alcohol by a woman during pregnancy, alters drug responsiveness in offspring; an examination of why children, adolescents and adults respond differently to antidepressants; studies of how perinatal stress, such as maternal separation, affects drug response and propensity to abuse drugs as an adult; and cardiovascular gene therapy.

The American Physiological Society program includes 16 societal or distinguished lectures and a Physiology Infocus session that focuses on novel technologies in physiology and medicine, such as advances in forensic medicine, new approaches in imaging, and the use of experimental evolution (selecting for particular physiological attributes in large laboratory populations) as a tool of physiological analysis. Other workshops include human subject research ethics and the challenge of presenting basic research in an anti-science, anti-evolution and anti-education era. Among topics for symposia or individual research presentations are: cancer and hypoxia (starving tumors of oxygen) ; pharmacogenomics of estrogen and cardiovascular disease; roles of intestinal epithelia and bacteria in inflammatory disease; and the potential benefits of
'"/>

Contact: Sylvia Wrobel
ebpress@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
25-Feb-2007


Page: 1 2 3 4 5

Related biology news :

1. 38 minority scientists receive travel fellowships to Experimental Biology 2007 in D.C.
2. Experimental Biology 2007 meets in Washington, D.C., April 28-May 2
3. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
4. Experimental RNA-based drug kills prostate cancer cells effectively and safely
5. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
6. Undergrads compete for American Physiological Society Bruce awards at Experimental Biology
7. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
8. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
9. Experimental evolution of yeast in the lab may illuminate early events in speciation
10. Advancing the biomedical frontier: Experimental Biology 2006
11. Experimental Biology 2006 meets in San Francisco April 1-5

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Experimental Biology Today Research Tomorrow Health April May

(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/15/2014)... pandemic risk from strains of influenza virus increases with ... to become complacent that the most substantial threats have ... Influenza pandemics arise when a new virus strain – ... – spreads in the human population. There have been ... worst of which – the 1918 Spanish Flu – ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... 20, 2014 PureTech , a science ... healthcare problems, announced today the closing of a ... from Invesco Perpetual, a $120 Billion group of ... PureTech,s existing pipeline forward and to advance new ... scientific creativity to really go for the big ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
Cached News: